Adrenal lesions: Common findings and pitfalls on 18F-FDG PET/CT

Document Type: Review Article

Authors

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Adrenal lesions are commonly observed during 18F-FDG PET/CT studies. Although, most of these lesions are considered benign, an important consideration in oncologic patients is metastasis. Benign lesions, such as adenomas usually present with low 18F-FDG uptake, although overlap with malignant lesions exist and clear SUV cut-off for distinguishing adrenal adenomas has not been established. Different criteria have been proposed to further characterize adrenal lesions, as benign or metastatic. Conventional imaging modalities have additional value when the degree of uptake is equivocal. In this review, we go through some of the common adrenal lesions, as well as discerning features that favor either benign or malignant etiology.

Keywords

Main Subjects


  1. Luketich JD, Burt ME. Does resection of adrenal metastases from non-small cell lung cancer improve survival? 1996 Dec;62(6):1614-6.
  2. Almeida MQ, Bezerra-Neto JE, Mendonça BB, Latronico AC, Fragoso MCBV. Primary malignant tumors of the adrenal glands. Clinics (Saopaulo). 2018 Dec 10;73(suppl 1):e756s.
  3. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008;195(3):363-9.
  4. Dong A, Cui Y, Wang Y, Zuo C, Bai Y. 18F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203(2):245-52.
  5. Webb WR, Brant WE, Major NM. Fundamentals of Body CT. 5th ed. Elsevier Health Sciences; 2019.
  6. Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, Sebag F, Leux C, Drui D, Dupas B, Renaudin K, Kraeber-Bodéré F. 18 F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37(9):1669-78.
  7. Dunnick N, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol. 1996;167(4):861-7.
  8. Chong S, Lee KS, Kim HY, Kim YK, Kim BT, Chung MJ, Yi CA, Kwon GY. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26(6):1811-24.
  9. Boland G, Lee M, Gazelle GS, Halpern EF, McNicholas M, Mueller P. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol.1998;171(1):201-4.
  10. Kawashima A, Sandler CM, Fishman EK, Charnsangavej C, Yasumori K, Honda H,  Ernst RD, Takahashi N, Raval BK, Masuda K, Goldman SM. Spectrum of CT findings in nonmalignant disease of the adrenal gland. Radiographics. 1998;18(2):393-412.
  11. Repko BM, Tulchinsky M. Increased F-18 FDG uptake in resolving atraumatic bilateral adrenal hemorrhage (hematoma) on PET/CT. Clin Nucl Med. 2008;33(9):651-3.
  12. Boneschansker L, Nijland M, Glaudemans AW, van der Meulen SB, Kluin PM, Dullaart RP. Adrenal hemorrhage causing adrenal insufficiency in a patient with antiphospholipid syndrome: increased adrenal 18F-FDG uptake. J Clin Endocrinol Metab. 2012 Sep;97(9):3014-5
  13. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. 2001;21(4):995-1012.
  14. Elsayes KM, Mukundan G, Narra VR, Lewis Jr JS, Shirkhoda A, Farooki A, Brown JJ. Adrenal masses: MR imaging features with pathologic correlation. Radiographics. 2004 Oct;24 Suppl 1:S73-86.
  15. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
  16. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging.2006;33(1):29-35.
  17. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192(4):956-62.
  18. Matsumoto S, Hosoya Y, Lefor AK, Haruta H, Ui T, Kurashina K, Saito S, Ashizawa K, Sasaki T, Kitayama J, Sata N. A black adrenal adenoma with high FDG uptake on PET/CT scan in a patient with esophageal carcinoma: A case report. Int J Surg Case Rep. 2018;44:118-21.
  19. Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [18 F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med. 2003;17(5):403-6.
  20. Akkuş G, Güney IB, Ok F, Evran M, Izol V, Erdoğan Ş, Bayazıt Y, Sert M, Tetiker T. Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma. Endocr Connect. 2019;8(7):838-45.
  21. Patel D, Gara SK, Ellis RJ, Boufraqech M, Nilubol N, Millo C, et al. FDG PET/CT scan and functional adrenal tumors: a pilot study for lateralization. World J Surg. 2016;40(3):683-9.
  22. Miyake H, Maeda H, Tashiro M, Suzuki K, Nagatomo H, Aikawa H,  Ashizawa A, Iechika S, Moriuchi A. CT of adrenal tumors: frequency and clinical significance of low-attenuation lesions. AJR Am J Roentgenol. 1989;152(5):1005-7.
  23. Elaini AB, Shetty SK, Chapman VM, Sahani DV, Boland GW, Sweeney AT, Maher MM, Slattery JT, Mueller PR, Blake MA. Improved detection and characterization of adrenal disease with PET-CT. Radiographics. 2007;27(3):755-67.
  24. Ludwig V, Rice MH, Martin WH, Kelley MC, Delbeke D. 2-Deoxy-2-[18F] fluoro-D-glucose positron emission tomography uptake in a giant adrenal myelolipoma. Mol Imaging Biol. 2002;4(5):355-8.
  25. Castinetti F, Verschueren A, Cassagneau P, Brue T, Sebag F, Daniel L, Taieb D. Adrenal myelolipoma: an unusual cause of bilateral highly 18F-FDG-avid adrenal masses. J Clin Endocrinol Metab. 2012;97(8):2577-8.
  26. Xie J, Dai J, Zhou W, Sun F. Adrenal ganglioneuroma: features and outcomes of 42 cases in a Chinese population. World J Surg. 2018;42(8):2469-75.
  27. Cai J, Zeng Y, Zheng H, Qin Y, Kaiyong T, Zhao J. Retroperitoneal ganglioneuroma in children: CT and MRI features with histologic correlation. Eur J Radiol. 2010;75(3):315-20.
  28. Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, Sugimura K. A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med. 2006;20(5):357.
  29. Linos D, Tsirlis T, Kapralou A, Kiriakopoulos A, Tsakayannis D, Papaioannou D. Adrenal ganglioneuromas: incidentalomas with misleading clinical and imaging features. Surgery. 2011;149(1):99-105.
  30. Farrugia F, Martikos G, Surgeon C, Tzanetis P, Misiakos E, Zavras N,Charalampopoulos A. Radiology of the adrenal incidentalomas. Review of the literature. Endocr Regul. 2017;51(1):35-51.
  31. Blake MA, Krishnamoorthy SK, Boland GW, Sweeney AT, Pitman MB, Harisinghani M, Mueller PR, Hahn PF. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol. 2003;181(6):1663-8.
  32. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H,Schoellnast H, Preidler KW, Samonigg H. Adrenocortical carcinomas and adrenal pheochromocytomas: mass  and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479-85.
  33. Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with iv administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188(4):970-4.
  34. Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, Prakash G, Khadilkar K, Pandit R, Lila A, Bandgar T. Genetic status determines 18F‐FDG uptake in pheochromocytoma/paraganglioma. J Med Imaging Radiat Oncol. 2017;61(6):745-52.
  35. Xi Y, Xu H, Zhang M, Hu J, Li B. Correlation between degree of malignancy of pheochromocytoma and standardized uptake value (SUV) measured by 18F-FDG PET/CT. J Nucl Med. 2011;52(supplement 1):1324.
  36. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212(1):35-41.
  37. Haddad T, Fard-Esfahani A, Vali R. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes. Nucl Med Commun. 2020;42(1):21-31.
  38. Fallahi B, Manafi-Farid R, Eftekhari M, Fard-Esfahani A, Emami-Ardekani A, Geramifar P, Akhlaghi M, Hashemi Taheri AP, Beiki D. Diagnostic efficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in euroendocrine tumors. Asia Ocean J Nucl Med Biol. 2019;7(2):129-140.
  39. Krestin GP, Steinbrich W, Friedmann G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology. 1989;171(3):675-80.
  40. Kim S, Lee S, Pak K, Kim I, Kim K. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. The Br J Radiol. 2018;91(1086):20170520.
  41. Perri M, Erba P, Volterrani D, Guidoccio F, Lazzeri E, Caramella D, Mariani G. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197(1):209-16.
  42. Kunikowska J, Matyskiel R, Toutounchi S, Grabowska-Derlatka L, Koperski Ł, Królicki L. What parameters from 18 F-FDG PET/CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging. 2014;41(12):2273-80.
  43. Gratz S, Kemke B, Kaiser W, Heinis J, Behr T, Höffken H. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging. J Int Med Res. 2010;38(2):633-44.
  44. Watanabe H, Kanematsu M, Goshima S, Kondo H, Kawada H, Noda Y, Moriyama N. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18 F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648-53.
  45. Guerin C, Pattou F, Brunaud L, Lifante J-C, Mirallié E, Haissaguerre M, Huglo D, Olivier P, Houzard C, Ansquer C, Hindié E, Loundou A, Archange C, Tabarin A, Sebag F, Baumstarck K, Taïeb D. Performance of 18F-FDG PET/CT in the characterization of adrenal masses in noncancer patients: a prospective study. J Clin Endocrinol Metab. 2017 Jul 1;102(7):2465-2472.
  46. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using 18F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14(4):468-75.
  47. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, Boland GW. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy—initial experience. Radiology. 2006;238(3):970-7.
  48. Esfahani AF, Chavoshi M, Noorani MH, Saghari M, Eftekhari M, Beiki D, Fallahi B, Assadi M. Successful application of technetium-99m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropin-producing bronchial carcinoid lung tumor: a case report. J Med Case Reports. 2010 Oct 18;4:323.
  49. Pruthi A, Basu S, Ramani SK, Arya S. Bilateral symmetrical adrenal hypermetabolism on FDG PET in paraneoplastic Cushing syndrome in breast carcinoma: correlation with contrast-enhanced computed tomography. Clin Nucl Med. 2010;35(12):960-1.
  50. Mittal B, Kumar R, Jois A, Singh H, Sood A, Bhattacharya A, Bhansali A. F-18 FDG PET/CT in patients with adrenocortical carcinoma-A tertiary care centre experience. J Nucl Med. 2017;58(supplement 1):122.
  51. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J,  B. R. Sigal, E. Baudin, M. Schlumberger. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol. 2006;91(3):920-5.
  52. Zhang J, Fan Y, Fu Z, Zhang X, Di L, Wang R. The role of 18F-FDG PET/CT in the management of bilateral adrenal gland lesions. J Nucl Med. 2018;59(supplement 1):1331.
  53. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-60.
  54. Frey S, Caillard C, Toulgoat F, Drui D, Hamy A, Mirallié É. Non-adrenal tumors of the adrenal area; what are the pitfalls? J Visc Surg. 2020;157(3):217-230.